MARKET
IPO

AVLN

Avalyn Pharma
AVLN
NASDAQ
Upcoming IPOs
Expected Listing Date: 2026-04-30
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-0.21~-0.18
-
-
591.13M~665.02M
-
2026-04-08
Public Filing
View Prospectus
Pending
Offering
Price Range: 16.00~18.00
Shares to be Issued: 11.80M
2026-04-29
Offering End Date
Offering Price: Pending
Post IPO Outstanding: 36.95M
2026-04-30
Listed
No Data
About AVLN
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company engaged in inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. The Company's pipeline is focused on treating pulmonary fibrosis. It has three approved oral antifibrotic therapies for pulmonary fibrosis: pirfenidone; nintedanib, and nerandomilast. Its clinically advanced candidates, AP01 and AP02, are inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis, respectively. It has completed ATLAS, a Phase Ib clinical trial of AP01 in patients with IPF. AP02 is being evaluated in AURA, a global Phase II clinical trial for the treatment of IPF. It is also advancing AP03 into a Phase I clinical trial. AP03 is a fixed-dose combination of inhaled pirfenidone, and nintedanib designed to deliver dual antifibrotic mechanisms with the potential for additive or synergistic benefit.

Webull offers Avalyn Pharma stock information, including NASDAQ: AVLN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVLN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVLN stock methods without spending real money on the virtual paper trading platform.